Condition (MeSH)
Lymphangioma
ClinicalTrials.gov lists 16 trials for Lymphangioma or a narrower condition beneath it. Palvella Therapeutics, Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 16 trials are tagged with Lymphangioma itself; the rest are tagged with a narrower condition beneath it.
When did Lymphangioma trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 5 |
| 2023 | 2 |
| 2022 | 1 |
| 2018 | 1 |
| 2010 | 1 |
| 2009 | 2 |
| 2000 | 1 |
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lymphangioma trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 2 |
| Phase 3 | 1 |
| Not applicable | 3 |
| Observational | 4 |
| Expanded access | 1 |
How many Lymphangioma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 8 |
| No longer available | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lymphangioma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Palvella Therapeutics, Inc. | 2 |
| Novartis Pharmaceuticals | 1 |
Which drugs are being tested for Lymphangioma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sirolimus | 2 |
| TARA-002 | 1 |
| SILDENAFIL | 1 |
| Mirdametinib | 1 |
| EVEROLIMUS | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alpelisib Pill | 3 |
| Sclerotherapy with intralesional bleomycin injection | 1 |
| PTX-022 | 1 |
| QTORIN 3.9% Rapamycin Anhydrous Gel | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lymphangioma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 8 | 1 |
| Fever | 5 | 1 |
| Airway/ lung | 3 | 1 |
| Pain- Abdomen- NOS | 3 | 1 |
| CVC port infection | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Lymphangioma? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an <i>N</i>-of-1 clinical trial. | eLife | 2022 | Yes |
| Bleomycin sclerotherapy in lymphangiomas of the head and neck region: a prospective study. | International journal of oral and maxillofacial surgery | 2021 | Yes |
| Efficacy and Clinical Outcomes of Bleomycin in the Treatment of Lymphangiomas: A Multicenter Experience. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 2021 | Yes |
| Propranolol for intractable diffuse lymphangiomatosis. | The New England journal of medicine | 2011 | Yes |
| Nonsurgical therapies for lymphangiomas: a systematic review. | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | 2008 | Yes |
Showing 5 of 15 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Rare lymphatic malformation | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Unspecified |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity.